TP508

Healing & repair In trials Human trials

Also called Chrysalin, Rusalatide acetate

A 23-amino-acid peptide copied from a non-clotting region of human thrombin. It signals blood vessel lining cells and stem cells to start repair, improving blood supply at injury sites. It has been tested for diabetic foot ulcers, fracture healing and radiation injury.

Evidence at a glance

Evidence
Human trials — Studied in people
Status
Reached clinical trials
Dosing
No human study has set a dose

Later trials did not clearly confirm the early results and development stalled.

What studies report

How it works

A fragment of thrombin that keeps the repair signalling without the clotting. It binds receptors on blood vessel lining and stem cells, restoring blood flow and recruiting repair cells to an injury.

Binds a receptor on the cell surface and signals inward

Where it acts

Joints & cartilage

The library groups this compound under Healing & repair. The diagram shows that target, not every tissue it reaches.

Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Wound and fracture healingDiabetic foot ulcersBlood flow at injury sites

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Reported real-world use, not evidence and not a recommendation.

Status: Reached phase 2/3 trials for wounds and fractures. Not approved.

Route
Subcutaneous injection, from reconstituted lyophilised powder
Sequence
AGYKPDEGKRGDACEGDSGGPFV
Formula
C97H146N28O36S
Molecular weight
2312.4 g/mol
CAS
121341-81-9
Available as
5 mg

Search PubMed for TP508 → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.